LIGHT-HCM

LIGHT-HCM: Weight Loss and GLP-1 Therapy to Ease Symptoms in Hypertrophic Cardiomyopathy - LIGHT-HCM: Weight Loss and GLP-1 Therapy to Ease Symptoms in Hypertrophic Cardiomyopathy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58112

Enrollment

Registered

2025-07-24

Start date

2026-01-06

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic cardiomyopathy, HCM thickend heart muscle

Interventions

GLP-1 agonist (according to current guidelines)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: ??Diagnosed with hypertrophic cardiomyopathy (left ventricular wall thickness = 15 milimeter)? Aged 18 and 80 years old  An indication to start GLP-1 agonists per current guidelines

Exclusion criteria

Exclusion criteria: Currently using GLP1- agonists Heart failure classified as NYHA IV/IV Terminal kidney insufficiencyHistory of acute pancreatitis or presence of chronic pancreatitisPregnancy

Design outcomes

Primary

Measure	Time frame
Quality of life	—

Secondary

Measure	Time frame
Improvement in physical performance and symptomatology (NYHA classification), weight loss (i.e. reduction in kilograms and waist circumference), change in echocardiographic parameters, cardiac fibrosis (MRI) and biochemistry.	—

Countries

Netherlands

Contacts

Public ContactR.A. Mangal

Erasmus MC, Universitair Medisch Centrum Rotterdam

r.mangal@erasmusmc.nl010 7040704

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 19, 2026